C. R. BARD, INC. (NYSE:BCR) Files An 8-K Submission of Matters to a Vote of Security Holders

C. R. BARD, INC. (NYSE:BCR) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item5.07

Submission of Matters to a Vote of Security
Holders.

(a) The registrant held its Annual Meeting of Shareholders on
April19, 2017.

(b) Described below are the matters voted upon at the Annual
Meeting of Shareholders and the number of votes for and against,
abstentions and broker non-votes, as applicable.

Proposal No.1 Each of the 11 director nominees was
elected. The results of the voting for each director nominee for
a term of one year are set forth below:

Nominee

Votes For VotesAgainst Abstain BrokerNon-Votes

David M. Barrett

58,325,877 352,121 53,846 4,731,155

Robert M. Davis

58,363,067 314,558 54,219 4,731,155

Herbert L. Henkel

56,308,859 2,378,722 44,263 4,731,155

John C. Kelly

58,496,992 192,046 42,806 4,731,155

David F. Melcher

58,049,317 639,077 43,450 4,731,155

Gail K. Naughton

57,661,030 1,030,224 40,590 4,731,155

Timothy M. Ring

55,557,823 2,143,438 1,030,583 4,731,155

Tommy G. Thompson

48,502,993 10,158,927 69,924 4,731,155

John H. Weiland

56,950,511 1,718,549 62,784 4,731,155

Anthony Welters

57,297,841 1,394,094 39,909 4,731,155

Tony L. White

55,291,377 3,366,467 74,000 4,731,155

Proposal No.2 Ratification of the appointment of KPMG LLP,
as the Companys independent registered public accounting firm for
fiscal year 2017 approved.

For

62,301,017

Against

1,085,353

Abstain

76,629

Proposal No.3 Approval of the compensation of our named
executive officers, on an advisory basis approved.

For

52,328,276

Against

6,151,035

Abstain

252,533

Broker non-votes

4,731,155

Proposal No.4 Say-on-Pay Frequency advisory vote on the
approval of the frequency of shareholder votes on compensation of
our named executive officers One Year.

1 Year

51,451,611

2 Years

171,500

3 Years

6,974,746

Abstain

133,987

Broker non-votes

4,731,155

The Company has considered these results and has determined that
it will hold an advisory vote to approve the compensation of its
named executive officers every year until the next required vote
on the frequency of advisory votes on the compensation of the
Companys named executive officers.


About C. R. BARD, INC. (NYSE:BCR)

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

C. R. BARD, INC. (NYSE:BCR) Recent Trading Information

C. R. BARD, INC. (NYSE:BCR) closed its last trading session up +0.69 at 254.77 with 653,276 shares trading hands.

An ad to help with our costs